CA19-9 Response to First-Line Neoadjuvant FOLFIRINOX and Second-Line Gemcitabine/Nab-Paclitaxel for Patients with Operable Pancreatic Cancer

被引：0
|
作者：
Sam Z. Thalji
Mandana Kamgar
Ben George
Mohammed Aldakkak
Kathleen K. Christians
Callisia N. Clarke
Beth A. Erickson
William A. Hall
Parag P. Tolat
Zachary L. Smith
Douglas B. Evans
Susan Tsai
机构：
[1] Medical College of Wisconsin,Department of Surgery, Division of Surgical Oncology, LaBahn Pancreatic Cancer Program
[2] Medical College of Wisconsin,Department of Medicine, Division of Medical Oncology, LaBahn Pancreatic Cancer Program
[3] Medical College of Wisconsin,Department of Radiation Oncology, LaBahn Pancreatic Cancer Program
[4] Medical College of Wisconsin,Department of Radiology, LaBahn Pancreatic Cancer Program
[5] Medical College of Wisconsin,Department of Medicine, Division of Gastroenterology and Hepatology, LaBahn Pancreatic Cancer Program
来源：
Annals of Surgical Oncology | 2023年 / 30卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：3013 / 3021
页数：8
相关论文
共 50 条
  • [21] Exceptional Response to Second-Line Gemcitabine/Nab-Paclitaxel Chemotherapy in Patients With Metastatic Pancreatic Adenocarcinoma
    Bukhari, Nedal
    Abdalla, Khalda
    Ibnshamsa, Fahad
    Alselwi, Waleed
    Al-Shakir, Shakir
    Alqahtani, Mohammed
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (10)
  • [22] Optimizing First-Line Chemotherapy in Metastatic Pancreatic Cancer: Efficacy of FOLFIRINOX versus Nab-Paclitaxel Plus Gemcitabine
    Di Costanzo, Francesco
    Di Costanzo, Federica
    Antonuzzo, Lorenzo
    Mazza, Ernesto
    Giommoni, Elisa
    CANCERS, 2023, 15 (02)
  • [23] Efficacy and Tolerability of Second-line Nab-paclitaxel and Gemcitabine After Failure of First-line FOLFIRINOX for Advanced Pancreas Cancer: A Single-institution Experience
    Zhang, Hanbo
    Kellett, Curtis
    Lambert, Pascal
    Kim, Christina A.
    CLINICAL COLORECTAL CANCER, 2018, 17 (03) : E451 - E456
  • [24] Biweekly Gemcitabine/Nab-Paclitaxel as First-line Treatment for Advanced Pancreatic Cancer
    Kokkali, Stefania
    Tripodaki, Elli-Sophia
    Drizou, Maria
    Stefanou, Dimitra
    Magou, Elpida
    Zylis, Dimosthenis
    Kapiris, Matthaios
    Nasi, Despoina
    Georganta, Chara
    Ardavanis, Alexandros
    IN VIVO, 2018, 32 (03): : 653 - 657
  • [25] CA19-9 Response to 1st-Line Neoadjuvant FOLFIRINOX and 2nd-Line Gemcitabine-Based Chemotherapy in Patients with Operable Pancreatic Cancer
    Thalji, S.
    Kamgar, M.
    George, B.
    Aldakkak, M.
    Christians, K.
    Clarke, C. N.
    Erickson, B.
    Hall, W.
    Tolat, P.
    Khan, A.
    Evans, D. B.
    Tsai, S.
    ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (SUPPL 1) : S20 - S20
  • [26] Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer
    Sezgin, Yasin
    Karhan, Ogur
    Aldemir, Mehmet Naci
    Urun, Muslih
    Ercek, Berrak Mermit
    Urakci, Zuhat
    Arvas, Hayati
    Tunc, Sezai
    Erdem, Mehmet
    Yerlikaya, Halis
    Ileri, Serdar
    Aydin, Ibrahim
    Bicer, Abdurrahman
    Komuroglu, Ahmet Ufuk
    Majidova, Nargiz
    Gokcek, Savas
    Demir, Hacer
    Yildiz, Sedat
    Akbas, Sinem
    Ozen, Esra
    Kahya, Burcu Ulas
    Sali, Muersel
    Anik, Hicran
    Aykut, Talat
    Araz, Murat
    Alkan, Ali
    Ozcelik, Melike
    Sakin, Abudllah
    Aykan, Musa Baris
    Mehtiyev, Mirmehdi
    Demir, Bilgin
    Baser, Mehmet Nuri
    Sonmez, Muge
    Gulturk, Ilkay
    Avci, Niluever
    Urvay, Semiha
    Arici, Mustafa Ozgur
    Kalender, Mehmet Emin
    Yildirim, Mustafa
    Solmaz, Ali Alper
    Gurbuz, Mustafa
    Ergun, Yakup
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [27] Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer
    Sezgin, Y.
    Karhan, O.
    Urakci, Z.
    Mecidova, N.
    Araz, M.
    Sakin, A.
    Ercek, B. M.
    Urun, M.
    Urvay, S.
    Aykan, M. B.
    Kocak, S.
    Arici, M. O.
    Avci, N.
    Alkan, A.
    Ozcelik, M.
    Aldemir, M. N.
    Ergun, Y.
    ANNALS OF ONCOLOGY, 2024, 35 : S930 - S930
  • [28] Folfirinox versus gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: a comparative propensity score study
    Williet, Nicolas
    Saint, Angelique
    Pointet, Anne-Laure
    Tougeron, David
    Pernot, Simon
    Pozet, Astrid
    Bechade, Dominique
    Trouilloud, Isabelle
    Lourenco, Nelson
    Hautefeuille, Vincent
    Locher, Christophe
    Desrame, Jerome
    Artru, Pascal
    Bidault, Anne Thirot
    Le Roy, Bertrand
    Pezet, Denis
    Phelip, Jean-Marc
    Taieb, Julien
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2019, 12
  • [29] Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer
    E Gabriela Chiorean
    Daniel D Von Hoff
    Josep Tabernero
    Robert El-Maraghi
    Wen Wee Ma
    Michele Reni
    Marion Harris
    Robert Whorf
    Helen Liu
    Jack Shiansong Li
    Victoria Manax
    Alfredo Romano
    Brian Lu
    David Goldstein
    British Journal of Cancer, 2016, 115 : 188 - 194
  • [30] Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer
    Chiorean, E. Gabriela
    Von Hoff, Daniel D.
    Tabernero, Josep
    El-Maraghi, Robert
    Ma, Wen Wee
    Reni, Michele
    Harris, Marion
    Whorf, Robert
    Liu, Helen
    Li, Jack Shiansong
    Manax, Victoria
    Romano, Alfredo
    Lu, Brian
    Goldstein, David
    BRITISH JOURNAL OF CANCER, 2016, 115 (02) : 188 - 194
12345